Lessons learned from the delivery of virtual integrative oncology interventions in clinical practice and research during the COVID-19 pandemic

Robert Knoerl, Carolyn S Phillips, Juliana Berfield, Heather Woods, Meghan Acosta, Anna Tanasijevic, Jennifer Ligibel, Robert Knoerl, Carolyn S Phillips, Juliana Berfield, Heather Woods, Meghan Acosta, Anna Tanasijevic, Jennifer Ligibel

Abstract

The outbreak of the coronavirus disease 2019 (COVID-19) and subsequent need for disease transmission mitigation efforts have significantly altered the delivery of cancer care (e.g., rise of telemedicine), including within the field of integrative oncology. However, little has been described about how National Cancer Institute-Designated Cancer Centers have transformed integrative oncology care delivery in response to the COVID-19 pandemic. The purpose of this commentary is to describe the delivery of integrative oncology clinical services and conduct of research at The Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute during the COVID-19 pandemic. Clinical services transitioned from an array of in-person appointment-based services, such as acupuncture and massage, and group programs, such as yoga and nutrition seminars to a combination of live-streamed and on-demand virtual group programs and one-on-one virtual appointments for services such as acupressure and self-care massage. Group program volume grew from 2189 in-person program patient visits in the 6 months prior to onset of the COVID pandemic to 16,366 virtual (e.g., live-streamed or on-demand) patient visits in the first 6 months of the pandemic. From a research perspective, two integrative oncology studies, focused on yoga and music therapy, respectively, were transitioned from in-person delivery to a virtual format. Participant accrual to these studies increased after the transition to virtual consent and intervention delivery. Overall, our clinical and research observations at Dana-Farber Cancer Institute suggest that the delivery of virtual integrative oncology treatments is feasible and appealing to patients. Trial Registration: NCT03824860 (Yoga); NCT03709225 (Music Therapy).

Keywords: Integrative medicine; Integrative oncology; Symptom management; Telemedicine.

Conflict of interest statement

Dr. Knoerl reports consulting honorariums from the Strategy Inc., Spark Healthcare, and System Analytic, outside the submitted work. The other authors have no conflicts of interest to declare that are relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Frequency of participant visits by program type at The Leonard P. Zakim Center for Integrative Therapies and Healthy Living at Dana-Farber Cancer Institute before and during the COVID-19 pandemic. Figure 1 describes the frequency of participant visits by program type at The Zakim Center from October 2019 to March 22, 2020 (in-person class offerings only), and March 23, 2020, to September 30, 2020 (virtual and on-demand class offerings only). Note: Exercise program offerings included classes such as yoga, strength training, Tai Chi, and Qigong. Expressive arts therapy program offerings included classes such as creative arts workshops and music therapy. Meditation and mindfulness program offerings included classes such as mind body resilience and mindfulness meditation

References

    1. Koonin LM, Hoots B, Tsang CA, et al. Trends in the use of telehealth during the emergence of the COVID-19 pandemic — United States, January–March 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1595–1599. doi: 10.15585/mmwr.mm6943a3.
    1. Meti N, Rossos PG, Cheung MC, Singh S. Virtual cancer care during and beyond the COVID-19 pandemic: We Need to Get It Right. JCO Oncol Pract. 2020;16:527–529. doi: 10.1200/op.20.00281.
    1. Mulvey TM, Jacobson JO. Covid-19 and cancer care: Ensuring safety while transforming care delivery. J Clin Oncol. 2020;38:3248–3251. doi: 10.1200/JCO.20.01474.
    1. Mullangi S, Schleicher SM, Aviki EM. Innovation in cancer care delivery in the era of COVID-19. JCO Oncol Pract OP. 2020;20:336. doi: 10.1200/op.20.00336.
    1. Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, Mileham KF, Nowakowski G, Schenkel C, Davis C, Bruinooge SS, Schilsky RL. Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020;16:417–421. doi: 10.1200/op.20.00275.
    1. Fleury ME, Farner AM, Unger JM. Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials. JAMA Oncol. 2020;7:131–132. doi: 10.1001/jamaoncol.2020.5748.
    1. Yun H, Sun L, Mao JJ. Growth of integrative medicine at leading cancer centers between 2009 and 2016: a systematic analysis of NCI-designated comprehensive cancer center websites. J Natl Cancer Inst - Monogr. 2017;2017:29–32. doi: 10.1093/jncimonographs/lgx004.
    1. Chan RJ, Howell D, Lustberg MB, Mustian K, Koczwara B, Ng CC, Kim Y, Nápoles AM, Dixit N, Klemanski D, Ke Y, Toh YL, Fitch MI, Crichton M, Agarawal S, Chan A. Advances and future directions in the use of mobile health in supportive cancer care: proceedings of the 2019 MASCC Annual Meeting symposium. Support. Care Cancer. 2020;28:4059–4067. doi: 10.1007/s00520-020-05513-x.
    1. Ream E, Hughes AE, Cox A et al (2020) Telephone interventions for symptom management in adults with cancer. Cochrane Database Syst Rev 2020
    1. Latte-Naor S, Mao JJ. Putting integrative oncology into practice: concepts and approaches. J Oncol Pract. 2019;15:7–14. doi: 10.1200/JOP.18.00554.

Source: PubMed

3
Tilaa